In this study, we show that the loss of the epilepsy-related gene Frrs1l in mice causes a dramatic reduction in AMPA receptor levels at the synapse. This change elicits severe motor and coordination disabilities, hyperactivity, cognitive defects, behavioural seizures and abnormal electroencephalographic (EEG) patterns.
Introduction
Ferric chelate reductase 1 like (FRRS1L) is a novel, highly conserved, brain specific protein whose functional characterisation has only recently been under investigation. Studies in patients have found nine families with recessive mutations in FRRS1L which result in severe intellectual disability, movement disorders, hypotonia and epilepsy (Madeo et al., 2016; Shaheen et al., 2016; Brechet et al., 2017) . In some patients, these clinical symptoms are accompanied by neurodegeneration in the cortex and cerebellum. Several families have now been diagnosed with this devastating condition, arguing for the inclusion of this gene in the diagnostic screening for epilepsy and dyskinetic disorders (Carecchio and Mencacci, 2017) .
The dramatic clinical consequences of carrying mutations in this gene point to an important neurological function for FRRS1L, which has not yet been elucidated, hence challenging efforts in therapeutic development.
Although named for its sequence similarity to ferric chelate reductase 1, FRRS1L has only a poorly characterised DOMON domain (DOpamine beta-MOnooxygenase N-terminal domain, IPR005018) and a transmembrane domain, with the ferric chelate reductase domain being absent, therefore its function is likely to be distinct from that of its namesake, FRRS1. Frrs1l is expressed in the central nervous system (CNS) and testis of adult mice and in developing embryonic forebrain (Madeo et al., 2016) . Further expression analysis in the adult mouse brain, shows Frrs1l expression in the excitatory neurons in the cerebral cortex, hippocampus and midbrain, medium spiny neurons in the striatum, granule cells in the dentate gyrus and Purkinje cells in the cerebellum (Zeisel, A et al., 2018 preprint) . Emerging studies have begun to unravel the role of FRRS1L in the CNS, importantly in AMPA receptor complex function.
FRRS1L co-localises with Calnexin in the endoplasmic reticulum (ER) of rat hippocampal neurons (Brechet et al., 2017) . Results of knockdown and exogenous overexpression studies in cultured hippocampal neurons suggest that FRRS1L, along with carnitine palmytoyltransferase 1c (CPT1C), is involved in the early stages of AMPA receptor complex biogenesis, binding to the core AMPA proteins, GLUA1-4, but dissociating before the final auxiliary proteins bind to make a functional receptor (Brechet et al., 2017) . Furthermore, reduction of FRRS1L levels in cultured hippocampal neurons leads to an overall decrease in AMPA receptor levels, as well as to modifications in synaptic transmission. In addition, interactions with dynein complex proteins suggest a potential role for FRRS1L in dynein based AMPA trafficking (Han et al., 2017) .
AMPA receptors are essential ionotropic glutamate receptors and mediate much of the fastexcitatory synaptic transmission in the brain. AMPA receptors are composed of four core proteins, GLUA1-4, which form a heterotetrameric complex at the centre of the receptor.
Associated with this core complex are a variety of auxiliary subunits with distinct roles in the maturation of AMPA receptors (Chen et al., 2000; Tomita et al., 2003; Kato et al., 2010; Schwenk et al., 2012 Schwenk et al., , 2014 Erlenhardt et al., 2016) . These auxiliary proteins have distinct roles in regulating the spatio-temporal activity of AMPAs, however many of these roles have yet to be elucidated.
The majority of human variants in patients with homozygous mutations in FRRS1L are predicted to lead to a premature stop codon and loss of the transmembrane domain, consequently leading to a loss of function. A knockout of the murine Frrs1l gene (Frrs1l tm1b/tm1b ) has been generated by the International Mouse Phenotyping Consortium (IMPC, http://www.mousephenotype.org/) to investigate the consequences of Frrs1l loss in vivo. Initial characterisation of this line uncovered a range of aberrant phenotypes including hyperactivity, abnormal gait, decreased grip strength and partial pre-weaning lethality (Koscielny et al., 2014; mousephenotype.org, accessed 01-06-2018 ). In the current study, we make use of this mouse line to explore its validity as a pre-clinical model and to investigate the phenotypic deficits in more depth. Moreover, we make use of this model to study whether a disturbance in AMPA receptor maturation is the mechanism underlying the pathology of the disorder providing new in vivo evidence for the pivotal role that Frrs1l has in AMPA receptor physiology.
Results

Loss of Frrs1l results in increased neonatal lethality, smaller size and early onset motor deficits
Frrs1l -/mice are born at expected Mendelian ratios; milk is present in the stomach, breathing is apparently normal and it is not possible to visibly distinguish between Frrs1l -/and wild-type littermates. However, >90% of Frrs1l -/neonates die between 12 and 24 hours after birth.
Analysis of numbers per genotype at weaning show a difference in expected ratios (p<0.0001), whereas at postnatal day 0 (P0) the ratio of genotypes is not significantly different to that expected (p=0.43) ( Fig. 1A) . Tissue was collected from any pups that were found dead in the first days after birth and genotyping carried out. We found mortality to be higher in Frrs1l -/with a greater proportion of homozygotes being found dead than would be expected by chance if this was not a genotype effect (p<0.001). Gross pathology was performed on pups at P0 and no obvious abnormalities were found in 44 tissues examined (data not shown). Frrs1l -/mice that survive past P2 continue to thrive to weaning and beyond. Five of the nine female homozygous mice were killed during the course of the study as they reached previously specified humane endpoints, including; seizure without full recovery (n=1), self-inflicted wounds and stereotypical behaviour (n=2), uncoordinated gait impinging on the ability to feed (n=1) and breathing difficulties (n=1).
In order to confirm that homozygous mutant mice no longer express Frrs1l, we conducted qPCR assays with primers spanning all five exons of the gene, including the targeted exon 3.
We confirmed no significant expression of Frrs1l in P0 and adult Frrs1l -/brains compared to wild-type littermates ( Fig. S1A and B ). Of the Frrs1l -lmice that survive to weaning, all show prominent reduced body weight when compared to littermate controls (P<0.05 from 6 months onwards) ( Fig. 1B) . However, the weight curve is not dissimilar to wild-type and does not show significant decline with age up to 14 months, suggesting a neurodevelopmental effect rather than a progressive wasting phenotype. Given the difference in body size, we further examined archived IMPC x-ray images and found that Frrs1 -lmice have a significantly shorter tibia length, and therefore smaller body size, than wild-type controls in both females (P<0.01) and males (P<0.05) (http://www. mousephenotype.org, 2015) . IMPC data also show no differences in body composition or calorimetric measurements of metabolic rate. In some cases, several years after onset of symptoms, human patients carrying mutations in FRRS1L express cerebellar atrophy and other pathological alterations in the brain (Madeo et al., 2016) . In Frrs1l -/cohorts, we found total brain weight to be approximately 10% less than wild-type controls (Frrs1l +/+ 0.459 ± 0.018 and Frrs1l -/-0.417 ± 0.009) (p<0.05), however no gross anatomical pathologies were evident Moreover, brain size differences were not significant after normalisation for body weight.
Animals that survived through early postnatal development were assessed using a focused battery of physiological, behavioural and motor function tests throughout adulthood.
Motor phenotyping was carried out in order to determine whether Frrs1l -/mice expressed abnormalities in movement and muscle force similar to those described in humans carrying FRRS1L mutations. We used a standard battery of tests including SHIRPA, grip strength and rotarod, followed by more complex testing of motor function using a horizontal ladder and a three week trial that measures progressive wheel running performance parameters. On visual inspection, Frrs1l -/mice have an abnormal gait which is evident at weaning and, in SHIRPA testing, show additional significant differences from wild-type littermate controls when assessed at 3, 6 and 9 months of age (P<0.05, P<0.01 and P<0.001 respectively) ( Table 1) .
Abnormalities highlighted in the SHIRPA test include; lack of co-ordination, demonstrated by inability to place feet correctly on a grid floor (p<0.001 at 9 months), loss of grip when climbing down a vertical grid (p<0.001 at 9 months), and muscle weakness indicated by an increased incidence of limb grasping (p<0.01 at all time points) (Table.1 and Fig.1C ). Limb grasping is also associated with defects in many neurological disorders, and it may indicate alterations in cortico-striatal circuits (Lalonde and Strazielle, 2011) . We measured grip strength at 3, 6 and 9 months of age to confirm quantitatively that the loss of Frrs1l resulted in muscle weakness. Indeed, grip force in all four limbs was significantly reduced in Frrs1l -/mice compared to wild-type controls (Fig. 1D ). The effect remained significant even after correcting for weight differences (3 months p<0.05, 6 months p<0.05, 9 months p<0.01). This loss of muscle strength is expressed from an early age without further deterioration, suggesting a developmental non-progressive phenotype.
Next, we assessed gait and motor co-ordination by performing three complementary tests at a single time point for each: a horizontal ladder challenge (Locotronic), a rotarod test and a wheel running paradigm. In the Locotronic challenge, Frrs1l -/mice showed an increased frequency of errors (misplacement of feet) whilst moving along the horizontal ladder when compared to their littermate controls (p<0.01) ( Fig. 1E ). This elaborates upon the previous observations in the SHIRPA test where homozygotes had a higher number of instances of feet falling through the bars of the grid. Supporting these data, Frrs1l -/mice also had a shorter latency to fall when placed on an accelerating rotarod (p<0.05) ( Fig. 1F ). In the motor function assessment by wheel running, no differences were observed between Frrs1l -/and wild-type mice during the first two weeks.
In the third week, the standard wheel was removed and replaced by a complex wheel with rungs missing at uneven intervals. After the new challenge was introduced Frrs1l -/were unable to run at all, showing a drop in running attempts to almost zero for the remainder of the third week (p<0.001) ( Fig. 1G ).
Thus, all tests evidence that mice lacking the Frrs1l gene suffer from a dramatic loss in muscle strength with loss of motor co-ordination and motor disabilities from an early age.
Frrs1l -/mice are hyperactive, have cognitive deficits and abnormalities in sleep
Previous IMPC-based assessment of these mice had indicated a hyperactivity phenotype. To confirm and further define this hyperactivity, mice were assessed at a number of time-points in group-housed conditions in the home cage to evaluate their activity continuously in an undisturbed, non-stressful environment. Frrs1l -/mice displayed increased activity when recorded at 10 weeks of age throughout both light and dark phases (p<0.05 light, p<0.0001 dark) and increased activity at six and nine months in the dark phase only (p<0.05 at both time points) ( Fig. 2A and B ). These home cage data indicate the hyperactivity is not a consequence of being introduced to a novel environment.
In the novel environment of the open field test at a single time point, Frrs1l -/mice exhibited increased activity in the whole arena demonstrated by a greater total distance moved (p<0.01) ( Fig. 2C ) and an increased velocity (p<0.01) ( Fig. 2D ), supporting the hyperactivity phenotype observed in the home cage analysis. The frequency to enter the centre of the arena and velocity in the centre of the arena were also significantly increased (p<0.05), however distance moved and duration in the centre were not different between Frrs1l -/and wild-type, indicating that the mice are hyperactive but that this is not necessarily related to an altered anxiety state in mutants ( Fig. S2A ).
Fig. 2 Deletion of Frrs1l causes hyperactivity, working memory deficits and abnormal sleep pattern. An
increase in distance moved is apparent in the home cage both during the light phase and the dark phase at 10 weeks old (p<0.05), and in the dark phase only at 6 months and 9 months (p<0.01) (A and B Learning disabilities are among the common features associated with intellectual disability, such as those seen in patients carrying mutations in FRRS1L. In the null mice, we evaluated working memory using the Y-maze forced alternation test. Interestingly, Frrs1l -/mice showed no preference for the novel arm ( Fig. 2E ) (p<0.05) suggesting a working memory deficit.
Previous studies have demonstrated that defects in AMPA receptor composition are associated with both intellectual disability and perturbed sleep patterns (Davies et al., 2017) .
Since FRSS1L has been proposed to play a role in AMPA receptor assembly, we assessed sleep status (immobility-defined sleep) in Frrs1l -/animals using passive infrared movement tracking (PIR) (Brown et al., 2016) . The total sleep of Frrs1l -/animals was significantly less than wild-type controls in the dark phase of the light cycle (time spent asleep in dark p=0.0002) We also examined the IMPC archive data on the Fear Conditioning paradigm, a test used to measure cognitive abilities, specifically those associated with non-declarative memory formation (LaBar and Cabeza, 2006) . Mice lacking FRRS1L have deficits in cued but not contextual fear conditioning, demonstrating an inability to learn the association between a tone and an aversive stimulus and therefore an impairment in implicit memory ( Fig 2H) .
Loss of Frrs1l causes abnormal EEG
Mutations in FRRS1L are associated with epileptic encephalopathy. One mouse died during a generalized convulsion. We observed episodes of behavioural arrest and lordotic posture in other Frrs1l -/animals. Therefore we carried out EEG recordings in Frrs1l -/animals to ascertain whether these episodes represent seizures. After the implantation of EEG transmitters in adult mice (n=2 Frrs1l /+/+ , n=3 Frrs1l -/-, and n=2 C57BL/6NTac), we recorded their EEG activity in their home-cage environment for 5 to 15 days. Large amplitude sawtooth-like spike trains were observed at delta frequency (ranging between 0.5 Hz -2Hz) in two of the mutants while abnormal high theta oscillation (ranging between 6 Hz -8Hz) was reported in the third Frrs1l -/animal. (B) . Two 5s representative spike trains were extracted and enlarged from recording in the Frrs1l -/-shown in (A). The waveform showed a dominant peak concentrated at 1 Hz -2 Hz, delta frequency after Fast Fourier Transform of traces from (B), data not shown.
Frrs1l -/mice exhibited frequent runs of high amplitude delta activity that were not present in control animals (C57BL/6NTac and Frrs1l /+/+ animals) ( Fig. 3A and B) . Although we did not capture discrete electrographic seizures, these results are consistent with the view that loss of Frrsl1 leads to a profound encephalopathy.
Decreased AMPA receptor protein levels in Frrs1l -/brain
In order to understand the mechanisms underlying the neurological and behavioural deficits described above, we investigated whether AMPA receptor levels were altered in vivo as a consequence of Frrs1l deletion, as suggested in earlier in vitro studies (Brechet et al., 2017) ).
We first examined whether the deletion of Frss1l would cause alterations in the gene expression levels of the four core AMPA receptor genes (Gria1, Gria2, Gria3 and Gria4) and found no differences between wild-type and Frrs1l -/mice either in P0 brain or in adult brain ( Fig.S1C and Fig.4A ). We next examined levels of three core AMPA receptor proteins (GLUA1, GLUA2 and GLUA4) in P0 brain and in 14 month-old cerebellum. In adult cerebellum, GLUA1, GLUA2 and GLUA4 levels were all significantly reduced in Frrs1l -/compared to wild-type controls (p<0.001, p<0.01, p<0.001 respectively) ( Fig. 4B and C) . In P0 brain only GLUA1 was significantly reduced, while alterations in immunoreactive band mobility were noted for both GLUA2 and GLUA4 (Fig. S3B) . To confirm that there was a specific loss of AMPA receptors in homozygotes rather than a general loss in synaptic number, we compared the levels of several standard synaptic proteins in adult cerebellum and P0 brain. Interestingly, we found no differences in expression of any of the synaptic proteins assessed (CAMKII, SNAP25, PSD95 and NMDA receptor) at any time point between wild-type and Frrs1l -/brains ( Fig. 4D -F and S3C and D). To investigate further, we counted the proportion excitatory synapses in the hippocampus and found no differences in synapse number between wild-type and Frrs1l -/brains (Fig. S4) . Collectively, these data
show that there is a significant reduction in AMPA receptor subunit levels present in adult
Frrs1l -/mice while synaptic numbers and levels of several key synaptic markers remain unchanged. Similar changes in protein level are observed in Frrs1l -/-P0 brain, which points to a developmental defect rather than a progressive degenerative change.
AMPA receptor glycosylation is incomplete leading to cytoplasmic retention in Frrs1l -/mice
Given that AMPA receptor protein levels were reduced while their transcriptional activity was unaffected, we concluded that these deficits in Frrs1l -/brain are most likely due to specific alterations in translational or posttranslational mechanisms. Interestingly, we observed that GLUA2 and GLUA4 band mobilities in western blots differ in wild-type and Frrs1l -/mice, with a more diffuse band in GLUA2 wild-type compared to in Frrs1l -/and a faster-running band seen in GLUA4. These differences could be related to differences in post-translational modification caused by a deficiency in this process in Frrs1l -/mice. As part of the maturation process of the AMPA receptor complex, the glycosylation of AMPA receptors goes through a series of modifications. Initially N-linked high mannose glycans are added to GLUA2 and GLUA4 in the endoplasmic reticulum (ER). Subsequently, AMPA receptor complexes are transported to the Golgi apparatus where glycans are clipped and modified to create more complex N-linked glycans. Assessing glycosylation state allows us not only to determine the extent of AMPA receptor glycosylation but also to establish the subcellular localisation of the AMPA receptor complex (Tucholski et al., 2013 (Tucholski et al., , 2014 .
We assessed the glycosylation status of GLUA2 and GLUA4 receptor subunits in control and mutant samples. Lysates from adult cerebellum were digested with endoglycosidase H (ENDO-H) and peptide:N-glycosidase F (PNGase) enzymes which cleave either immature glycosylated moieties, such as high mannose glycans, or all glycosylated forms, respectively ( Fig. 5A ). We found that, when digested with PNGase, all immunoreactive bands showed an apparent size shift, indicating that the subunits are typically glycosylated in both wild-type and Frrs1l -/brain. When incubated with ENDO-H, in wild-type mice, only a small proportion of the GLUA2 and GLUA4 were digested, amounting to approximately 18% of total protein for both.
Therefore the majority of GLUA2 and GLUA4 in wild-type is insensitive to ENDO-H and thus must be maturely glycosylated. Conversely, in Frrs1l -/a greater proportion (p<0.01) of the GLUA2 and GLUA4 was digested with ENDO-H, amounting to approximately 65% of GLUA2 and 45% of GLUA4 total protein. This demonstrates a higher level of immature glycosylation of the receptor subunits in the absence of FRRS1L. Based on previous work following AMPA receptor localisation and glycosylation (Tucholski et al., 2013 (Tucholski et al., , 2014 , this result also suggests that GLUA2 and GLUA4 AMPA receptor processing is stalled at the level of the Golgi apparatus in Frrs1l -/mice.
This increase in immaturely glycosylated AMPA receptors in Frrs1l -/mice might result in a reduction in receptor levels at the synaptic membrane. To investigate, we carried out synaptic fractionation to determine the proportional levels of AMPA receptor in the cytoplasmic and post-synaptic membrane fractions of adult forebrain. These data show that more than double and GLUA4 digestion with , approximately 18% of wild-type GLUA2 and GLUA4 is digested compared to approximately 65% and 45% respectively in Frrs1l -/-. Localisation of AMPA receptors is altered, with increased amount of AMPA receptor in the cytoplasm rather than the synapse in Frrs1l -/-. GLUA1 proportions in the cytoplasm and the synapse were not altered, and overall levels of GRIN1 were unchanged between Frrs1l -/and wildtype controls. Data analysed using students t-test (n=3 Frrs1l -/-, n=3 Frrs1l +/+ ). Percentage of total GLUA2 and 4 (A) are mean and standard deviation.
the amount of both GLUA2 and GLUA4 are retained in the cytoplasm of Frrs1l -/compared to wild-type, leading to a reduction in the post-synaptic fraction (Fig. 5B) . Interestingly, for GLUA1, levels were proportionally lower in the post-synaptic fraction in mutant brain without evidence for retention in the cytoplasmic fraction. Additionally, NMDAR levels in the postsynaptic fraction were not affected by Frrs1l deficiency (Fig 5C) .
In conclusion, these results reveal that the loss of FRRS1L leads to a specific reduction in the levels of the AMPA receptor subunit proteins at the synapse in vivo without obvious changes in other synaptic components. Functional FRRS1L is necessary for the mature glycosylation of at least GLUA2 and GLUA4. Loss of FRRS1L leads to incomplete post-translational processing of AMPA receptors, increased retention of AMPA receptors in the cytoplasmic fraction and, consequently, a decrease in levels of functional AMPA receptors at the synapse.
Discussion
In previous work we described several families with homozygous mutations in FRRS1L (Madeo et al., 2016) . The main symptoms in the affected children are encephalopathy, epilepsy and progressive choreoathetosis. All children have severe intellectual disability with no expressive speech, impaired volitional movement and chorea developing into hypokinesia and seizures. This is a rare disease only recently characterized, although it is expected that there will be more cases in the near future, especially considering the gene is now included in the screening for infantile epilepsy and dyskinesia (GTR test ID GTR000551789.3).
Our data demonstrate that complete lack of Frrs1l has substantial effects on post-natal survival, as well as body weight, motor co-ordination, activity, sleep, effects on cognition and abnormal EEG. Anomalies are present from an early age with no progressive deterioration, suggesting a neurodevelopmental defect, rather than an age-associated neurodegenerative disorder. Interestingly Frrs1l -/mice show sleep disturbances. Although sleep disturbances have not been documented in human patients with mutations in FRSS1L, it is well known that sleep disruption is often a feature of numerous neurological disorders, particularly epileptic disorders (Crespel, Baldy-Moulinier and Coubes, 1998; Kothare and Kaleyias, 2010) .
Importantly, we report the occurrence of behavioural seizures in these mice, although we were unable to capture them on EEG recording, which instead showed prominent runs of delta waves. Thus, all these phenotypic features resemble the symptoms seen in patients carrying homozygous mutations in the FRRS1L gene, making these mice a very useful model of disease. The use of these mice allowed us to provide compelling in vivo evidence that FRRS1L
is critical for AMPA receptor complex maturation, defects in which result in dramatic phenotypic effects in mice.
In Frrs1l -/mice we found a highly significant reduction in the levels of core AMPA receptor proteins from birth through to adulthood, and importantly, AMPA receptor subunits lack complete posttranslational processing and mature glycosylation. Thus, these data provide in vivo evidence that FRRS1L is crucial for the correct biogenesis and maturation of AMPA receptors, which elicits dramatic motor alterations, dyskinesia phenotypes, and abnormal electrographical activity in Frrs1l -/mice.
Previous work using a CRISPR/Cas9 deletion of Frrs1l in mouse primary neurons shows that it leads to an overall reduction in GLUA1 levels (Han et al., 2017) . Here we confirm that GLUA1 levels are lower in vivo but we extend this observation to other GLUAs. Crucially, we show that the low AMPA receptor levels are not a consequence of degeneration nor are they associated with a general reduction in synaptic number in Frrs1l -/mice. Thus the role of FRSS1L seems to be specific in the maturation of AMPA receptor complexes. Importantly we found that it is not only the levels of AMPA receptors that are low, but also their maturation (glycosylation) and location at synapses. AMPA receptors which are not fully glycosylated are not functional (Tomita et al., 2003; Tucholski et al., 2014) , and so the presence of functional receptor complexes in the membrane are substantially deficient in mutants. We also provide evidence that FRSS1L has a critical role in the glycosylation/maturation of GLUA2 and GLUA4. It is interesting to note that the glycosylation of GLUA2 and GLUA4 is not totally abolished,
indicating that there could be partial compensation for FRRS1L by another protein or perhaps a parallel mechanism, independent of FRRS1L, which may be involved in AMPA receptor biogenesis.
Supporting these data, the Frrs1l -/mouse phenotype resembles that of null mutations in other genes associated with synthesis, transport and stability of AMPA receptors, such as Cpt1c (Carrasco et al., 2013) , Shank3 (Wang et al., 2011) and Stargazin (Letts et al., 1998; Menuz and Nicoll, 2008) . CPT1C is proposed to play a similar role to FRRS1L in AMPA receptor biogenesis (Brechet et al., 2017) . As might be expected, many phenotypic similarities can be found in knockouts of Cpt1c and Frrs1l. Carrasco et al (Carrasco et al., 2013) demonstrate that Cpt1c knockout mice have poor co-ordination, reduced latency to fall from a rotarod, ataxia and reduced grip strength. Conversely, the Cpt1c knockout mice show hypoactivity, whereas we demonstrate that Frrs1l -/mice are hyperactive. It is possible that this inconsistency is due to the different methods of activity test measurement in the two studies. Interestingly, Cpt1c knockout mice show reduced levels of AMPA receptor subunit proteins, with no change in AMPA receptor gene expression by qPCR, mirroring the results seen in Frrs1l -/mice (Fadó et al., 2015) and substantiating the argument that these two proteins are involved in the same process. Null mutations in mouse Shank3, a scaffold protein in the post synaptic density, results in abnormal foot placement and reduced latency to fall from a rotarod, both of which are seen in Frrs1l -/mice. However Shank3 mice also show decreased locomotion which is contrary to the phenotype of Frrs1l -/-. The Stargazin mouse has a mutation in PSD-95, a member of the AMPA receptor complex, which causes a general decrease in AMPA receptor function and phenotypes that overlap with Frrs1l mutants, specifically ataxia and impaired co-ordination (Letts et al., 1998; Menuz and Nicoll, 2008) . Stargazin mice also have a similar change in glycosylation of GLUA2 as seen in Frrs1l -/-. It is noticeable that one of the main features of patients with homozygous mutations in FRRS1L and in the stargazin mouse model is the presence of seizures. Crucially, we are able to detect behavioural seizures in this study of Frrs1l -/mice.
In summary, we provide evidence for the validity of the Frrs1l -/mouse as a model of disease, expressing phenotypic features that resemble many of the clinical symptoms in patients. At the molecular level we have demonstrated that FRSS1L has a fundamental role in AMPA receptor biology, impacting in the total AMPA receptor levels as well as a reduction in the proportion of AMPA receptors available at synapses. This mouse is potentially an important pre-clinical model not only to support the development of therapeutics for such patients, but also as a valuable resource to further understand the complexities of AMPA receptors and glutamate signalling in the brain.
Materials and Methods
Mice
All mice (Mus musculus) were maintained and studied in accordance with UK Home Office Frrs1l tm1a/+ mice were derived from C57BL6/NTac ES cells (Skarnes et al, 2011) .The null allele (tm1b) was created by carrying out an IVF using Frrs1l tm1a/+ sperm and C57BL6/NTac oocytes.
Soluble cell permeable cre (TAT-Cre (Tat-NLS-Cre, HTNC, HTNCre), Excellegen, Rockville, USA) was added to two cell Frrs1l tm1a/+ embryos to generate the Frrs1l tm1b/+ allele. The cre excises the selection cassette and exon 3 of the Frrs1l gene, creating a null allele washing to remove the soluble cre, the IVF procedure was completed as normal. The
Frrs1l tm1b/+ were crossed to C57BL6/NTac and then intercrossed to create Frrs1l tm1b/tm1b , Frrs1l tm1b/+ and Frrs1l +/+ cohorts. Hereafter Frrs1l tm1b/tm1b will be referred to as Frrs1l -/-.
Behavioural phenotyping tests.
For all behavioural phenotyping tests, mice were taken to the test room at least 20 minutes prior to the start of the test to acclimatise. Phenotyping equipment was cleaned with 70% ethanol/IMS or 2% Distel between tests.
Investigators were blind to genotype during all phenotyping tests.
All phenotyping except fear conditioning was carried out on female mice due to issues of reduced viability. SHIRPA, grip strength and home cage activity monitoring were assessed at 3, 6 and 9 months. All other tests were carried out on only one occasion at the ages indicated below. For behavioural tests, sample size was calculated using power equations based on previous data obtained on C57BL/6NTac mice. Sample sizes in the later time points are smaller due to the loss of several mice with welfare concerns.
Fear conditioning. Fear conditioning was carried out on a separate cohort of male mice prior to the rest of the study (n=7 C57BL/6NTac; n=8 Frrs1l +/-, n=7 Frrs1l -/-). These mice were part of the IMPC phenotyping pipeline, the remainder of the IMPC phenotyping data is published on the IMPC data portal (IMPC, http://www.mousephenotype.org/, Koscielny et al., 2014) .
Open Field Activity. Open field activity was used to assess locomotion in a novel environment.
At 10 weeks of age (+/-1 week), mice were placed in square arenas (44x44cm) in a small testing room. A minimum of two and a maximum of four mice were tested at one time, one mouse per arena. Lighting was set at 150-200 lux. Mice were video tracked for 20 minutes and data analysed using Ethovision XT software (Noldus, Netherlands) and parameters such as distance moved, velocity and duration moving were recorded in various zones over the entire 20 minute period (Joyce et al., 2016) . (n=7 Frrs1l +/+ ; n=10 Frrs1l -/-).
SHIRPA. A semi-quantitative assessment was carried out using a modified SmithKline
Beecham, Harwell Imperial College, Royal London Hospital phenotype assessment (SHIRPA)
protocol. Behaviour and dysmorphology parameters were recorded as previously described (Masuya et al., 2005) (n=8 Frrs1l +/+ ; n=9 Frrs1l -/at three months, n=8 Frrs1l +/+ ; n=9 Frrs1l -/at 6 months, n=8 Frrs1l +/+ ; n=7 Frrs1l -/at 9 months).
Grip Strength. Grip strength was assessed at 13 weeks of age (+/-1 week) using the Grip Strength Test (BioSeb, Chaville, France). Readings were taken from all four paws, three times per mouse at each age, as per manufacturer's instructions (Joyce et al., 2016) . (n=8 Frrs1l +/+ ;
n=8 Frrs1l -/at three months, n=8 Frrs1l +/+ ; n=8 Frrs1l -/at 6 months, n=6 Frrs1l -/-n=6 Frrs1l +/+ at 9 months).
Home cage analysis. Group housed animals were monitored as described (Bains et al., 2016) .
Briefly, group housed mice were tagged with RFID micochips at 9 weeks of age and placed in the Home Cage Analysis system (Actual Analytics, Edinburgh) which captured mouse behaviour using both video tracking and location-tracking using RFID co-ordinates (Bains et al., 2016) . (n=8 Frrs1l +/+ ; n=8 Frrs1l -/at all time points).
Locotronic. Paw placement was analysed using Locotronic (Intelli-Bio, France) at 13 weeks of age (+/-1 week). Briefly, animals were assessed as they moved down a corridor with a horizontal ladder as its base. Animals were motivated to travel from a lighter starting area at one end to a darker finish area at the other end (bars: 3 mm diameter; spaced by 7 mm).
Infrared sensors above and below each bar space recorded any errors of paw placement.
Trials were discounted if the mouse took more than 30s to move to the finish after exiting the start area (n=8 Frrs1l +/+ ; n=7 Frrs1l -/-).
Rotarod. To assess co-ordination and motor learning, 22-week-old mice (+/-2 weeks) were placed on an accelerating rotarod (Ugo Basile), with rotor speed increasing from 4rpm up to 40rpm over a five-minute period. The time taken for the mouse to fall from the rod was recorded. This was repeated three times on one day with a 15 minute inter trial interval (Corrochano et al., 2012) 
Y-maze. A forced alternation y-maze test was used to evaluate short term working memory in mice at 14-20 weeks of age. Mice were placed in a y-maze with access to one arm blocked, they were then free to explore the start arm and the 'familiar' arm for ten minutes. Mice were returned to the home cage for a two minute inter trial interval, during which the maze was cleaned to remove odour cues. The mice were then returned to the maze, with access to all three arms open for five minutes. Mice were video tracked at all times using Ethovision software (Noldus, Netherlands) (Sanderson and Bannerman, 2012) . (n=7 Frrs1l +/+ ; n=7
Frrs1l -/-).
Motor function assessment by wheel running. For further assessment of motor function, 45-50
week old mice were singly housed and placed in cages containing a running wheel as previously described (Mandillo et al., 2014) (TSE systems Bad Homburg, Germany). Number of rotations, time running, number of bouts and speed were measured. After two weeks with the standard wheel, this was replaced with a complex wheel which had specific rungs removed in order to test co-ordination and learning. Parameters were recorded for a further week (n=5 Frrs1l +/+ ; n=5 Frrs1l -/-).
Passive Infrared screen for immobility defined sleep (PIR)
At 1 year, mice were analysed for circadian activity and immobility defined sleep using the COMPASS system as described (Brown et al., 2016) . Mice were individually housed and data captured for 5 days in a 12:12 LD cycle, followed by 9 days in constant darkness. Data analysis was performed using custom python scripts and excels sheets, developed in house. Circadian analysis was performed by converting activity data from PIR to AWD files for analysis on Clocklab (Actimetrics, Illinois) or Actiwatch Sleep analysis software (CamNtech, Cambridge) (n=5 Frrs1l +/+ ; n=6 Frrs1l -/-).
Quantitative PCR analysis
RNA extraction from P0 brain tissue or cerebellum of 14 month old mice was performed using an RNeasy kit (Qiagen) (n=5 Frrs1l +/+ ; n=5 Frrs1l -/at P0, n=4 Frrs1l +/+ ; n=4 Frrs1l -/at 14 months). cDNA synthesis was performed using the High Capacity cDNA RT kit (ThermoFisher Scientific) starting with 2µg of total RNA. cDNA for qPCR amplification was used at a final concentration of 10 ng per well. All the reactions were run in triplicate. Fast Sybr Green mastermix from ThermoFisher Scientific was used and the reactions had a final volume of 20µl. Primers were at a final concentration of 360nM. Primers were designed to span exonexon boundaries and are listed in Supplemental Table 1 . Fold changes were calculated using the 2-ddCt method using the 7500 Software v2.0.6 and normalized using S16 endogenous reference genes relative to WT genotype (Livak and Schmittgen, 2001) .
Immunoblot analysis
Adult cerebellum or P0 whole brains were bisected and one fraction homogenized in RIPA buffer (150 mM NaCl, 1% NP40, 0.5% Na deoxycholate, 0.1% SDS, 50 mM Tris pH 7.5) with phosphatase and protease inhibitor cocktails (Roche), using lysing matrix tubes D (MP Biomedicals, Germany) and a Fast-Prep-24 homogenizer at 4°C. Homogenates were centrifuged at 12,000 g 4°C for 20 min. 30 μg of soluble fractions were resolved by SDS-PAGE (NUPAGE system, Invitrogen) and transferred to Nitrocelulose membranes (Millipore)
for western-blot analysis. The following primary antibodies were used: rabbit monoclonal anti-b-actin (1/3000 Sigma A2066); mouse anti-α tubulin (1/3000 Sigma T9026), rabbit anti-GLUA1
(1/1000 Millipore 1504) mouse anti-GLUA2 (1/800 Millipore MAB397), rabbit anti-GLUA4
(1/1000 Millipore AB1508), mouse anti-CAMKII (1/200 Proteintech 20665-1) mouse anti-SNAP25 (1/500 Biolegend 836304), rabbit anti-PSD-95 (1/1000 Cell Signalling 3450T), and mouse anti-GRIN1 (for NMDA receptor, 1/1000 Novus, NB300-118).
Protein was visualized using anti-mouse (P/N 926-68070) or anti-rabbit (P/N 926-32211) secondary antibodies IRDye ® (Li-Cor Biosciences) at 1:10000 dilutions and quantified using the scanning infrared Odyssey imaging system CX (Li-Cor Biosciences).
All antibodies used are previously validiated, published and purchased from commercial suppliers.
Glycosylation assay
Bisected adult cerebellum was homogenised in RIPA buffer as above. 60ug of soluble fraction was de-natured with glycoprotein denaturing buffer for 10 minutes at 100 degrees, followed by immediate immersion in ice. Samples were divided into three aliquots and glycobuffer added, followed by Endo-H (QABio, E-EH02), PNGase (New England Biolabes, P0704S) or water. All samples were incubated at 37 degrees for 1 hour. Half of each sample, containing 10μg of protein, was resolved by SDS-PAGE (NUPAGE system, Invitrogen) and transferred to Nitrocellulose membranes for Western blot analysis.
Post-Synaptic Fractionation enrichment.
Synaptic fractionation was conducted following a modified protocol using a single cerebral hemisphere homogenized using a Dounce homogenizer in Syn-PER™ Synaptic Protein Extraction Reagent (Thermo Scientific, IL, USA) with phosphatase and protease inhibitor cocktails (Roche). Homogenates were cleared by centrifugation at 1200 x g for 10 min and then at 15000 x g for 20 min at 4 degrees. The supernatant contains the cytosolic fraction and the pellet the crude synaptosomal fraction. The pellet was resuspended in syn-PER lysis buffer with 0.1mM CaCl2 and 2% Triton X-100, 40mM Tris, pH6 and incubated on ice, with gentle agitation for 30 minutes. Following a centrifugation at 40,000 x g for 30 minutes at 4°C, the pellet was washed with 1% Triton X-100, 20mM Tris, pH6. Then the sample was centrifuged again, resuspended in 1% Triton x-100, 20mM Tris, pH8 and incubated on ice with gentle agitation for 30 minutes. After another centrifugation at 40,000 x g for 30 minutes at 4°C the pellet, containing the post-synaptic density, was resuspended in 1% Triton x-100, 20mM Tris, pH8, precipitated by adding 10 volumes of ice cold acetone at -20 C overnight and subsequently centrifuged at 15,000 x g for 30 minutes, at 4°C. The pellet containing the postsynaptic fraction was resuspended in 5 % SDS. After protein quantification with a DC assay (BioRad), 15 μg of protein from the post-synaptic fraction and 20 μg from the cytoplasmic fraction were resolved in precast 3-8% SDS-PAGE gels and transferred to Nitrocellulose membrane (Invitrogen) for Western blot analysis.
Synapse Counts
Formalin fixed wax embedded sections of whole brain were dewaxed, the antigen was unmasked using sodium citrate buffer solution (ph 6.0) at 80 °C for 30 minutes. Sections were next washed in phosphate-buffered saline (PBS, Ph 7.4) and processed for immunofluorescence. After a blocking step in PBS containing 0.05% Triton X-100 and 10% normal goat serum (NGS), sections were incubated overnight at 4 °C with the antibodies anti-VGLUT1 (1:200, Synaptic System. Antibody was diluted in PBS with 3% normal goat serum and 0.05% Triton X-100. Sections were then washed in PBS (4 x 10 min) and incubated for 1 h at room temperature with a secondary anti-rabbit antibody conjugated with Alexa Fluor 488 (Invitrogen). After several PBS rinses, sections were mounted on glass slides and observed with a Zeiss LSM 700 confocal microscope (Carl Zeiss AG). Confocal z-stacks covering the whole depth of the slices (1024 x 1024 pixels) spaced by 1.05 µm were acquired at 63 x.
VGLUT1 positive puncta were analysed on confocal images using Fiji software. Caudal sections were used to analyse both stratum oriens and radiatum of the CA1 region of the hippocampus.
